Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | MGAT2 | Q10469 | 2/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19855089 | 1.00 | ESR2 (0.32) | ESR2DGAT1SOAT1MGAT2FFAR4 | |
| SCHEMBL19853848 | 0.91 | FPR2 (0.33) | ESR2DGAT1SOAT1FFAR4 | |
| SCHEMBL19855074 | 0.91 | FPR2 (0.33) | ESR2DGAT1SOAT1FFAR4 | |
| SCHEMBL19853843 | 0.89 | CYP2C9 (0.36) | DGAT1SOAT1 | |
| SCHEMBL19855086 | 0.89 | CYP2C9 (0.36) | DGAT1SOAT1 | |
| SCHEMBL20322606 | 0.89 | FFAR4 (0.32) | FFAR4 | |
| SCHEMBL19853858 | 0.89 | PTPN11 (0.37) | DGAT1 | |
| SCHEMBL19855363 | 0.89 | MGAT2 (0.34) | ESR2DGAT1SOAT1MGAT2FFAR4 | |
| SCHEMBL19855095 | 0.88 | FFAR4 (0.33) | FFAR4 | |
| SCHEMBL20322746 | 0.88 | PPARG (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| EP-3351525-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | C1S, CCND1, C5 | ESR2 1953/4885DGAT1 2150/4885SOAT1 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.